Status:
COMPLETED
EMR Tool Impact on HIT Documentation and Management
Lead Sponsor:
Rush University Medical Center
Conditions:
Heparin
Thrombocytopenia
Eligibility:
All Genders
18-90 years
Brief Summary
Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse drug reaction to heparin products which results in a prothrombotic state. Heparin-induced thrombocytopenia generally occurs several...
Detailed Description
Heparin-induced thrombocytopenia is a unique form of drug induced thrombocytopenia associated with increased clotting risk. The incidence of HIT ranges from 0.1% to 5%. Heparin-induced thrombocytopeni...
Eligibility Criteria
Inclusion
- HIT-Ab ordered
- Aged ≥ 18 years of age
Exclusion
- Previously documented and confirmed HIT allergy prior to placement for new HIT-Ab
- Pregnancy
Key Trial Info
Start Date :
January 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2017
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT05439265
Start Date
January 1 2014
End Date
April 1 2017
Last Update
June 30 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rush University Medical Center
Chicago, Illinois, United States, 60612